Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Current Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Current Assets for 3 consecutive years, with $112.7 million as the latest value for Q4 2025.

  • For Q4 2025, Current Assets fell 40.27% year-over-year to $112.7 million; the TTM value through Dec 2025 reached $112.7 million, down 40.27%, while the annual FY2025 figure was $112.7 million, 40.27% down from the prior year.
  • Current Assets hit $112.7 million in Q4 2025 for Artiva Biotherapeutics, down from $129.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $188.6 million in Q4 2024 and bottomed at $49.7 million in Q2 2024.
  • Average Current Assets over 3 years is $128.8 million, with a median of $139.3 million recorded in 2025.
  • On a YoY basis, Current Assets climbed as much as 199.64% in 2025 and fell as far as 40.27% in 2025.
  • Artiva Biotherapeutics' Current Assets stood at $79.8 million in 2023, then surged by 136.32% to $188.6 million in 2024, then crashed by 40.27% to $112.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $112.7 million, $129.5 million, and $149.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.